INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR 2024
International Isotopes (INIS) reported strong financial results for Q4 and fiscal year 2024. Q4 revenues increased 24% to $3.9 million, while full-year revenues reached a historic high of $13.9 million, up 13% year-over-year. The company achieved significant profitability improvements, with Q4 net income rising 325% to $245,819 and full-year net income turning positive at $8,574.
The company's performance was driven by growth in Theranostics Products, which saw a 17% annual increase to $8 million, and record revenue in Cobalt Products, up 128% to $2.4 million. However, Nuclear Medicine products experienced a 20% decline due to raw material shortages. The company's new Medical Devices segment is preparing for product commercialization in 2025.
Non-GAAP EBITDA improved by 332% to $615,934, while adjusted EBITDA reached $1.2 million, a 379% increase from 2023.
International Isotopes (INIS) ha riportato risultati finanziari solidi per il quarto trimestre e l'anno fiscale 2024. Le entrate del quarto trimestre sono aumentate del 24% a 3,9 milioni di dollari, mentre le entrate annuali hanno raggiunto un massimo storico di 13,9 milioni di dollari, con un incremento del 13% rispetto all'anno precedente. L'azienda ha ottenuto significativi miglioramenti nella redditività, con un utile netto del quarto trimestre in crescita del 325% a 245.819 dollari e un utile netto annuale diventato positivo a 8.574 dollari.
Le performance dell'azienda sono state guidate dalla crescita dei Prodotti Teranostici, che hanno registrato un incremento annuale del 17% a 8 milioni di dollari, e dai ricavi record dei Prodotti di Cobalto, aumentati del 128% a 2,4 milioni di dollari. Tuttavia, i prodotti di Medicina Nucleare hanno subito un calo del 20% a causa della carenza di materie prime. Il nuovo segmento dei Dispositivi Medici dell'azienda si sta preparando per la commercializzazione dei prodotti nel 2025.
Il EBITDA non GAAP è migliorato del 332% a 615.934 dollari, mentre l'EBITDA rettificato ha raggiunto 1,2 milioni di dollari, con un aumento del 379% rispetto al 2023.
International Isotopes (INIS) reportó resultados financieros sólidos para el cuarto trimestre y el año fiscal 2024. Los ingresos del cuarto trimestre aumentaron un 24% a 3,9 millones de dólares, mientras que los ingresos anuales alcanzaron un máximo histórico de 13,9 millones de dólares, un incremento del 13% en comparación con el año anterior. La empresa logró mejoras significativas en la rentabilidad, con un ingreso neto del cuarto trimestre que creció un 325% a 245.819 dólares y un ingreso neto anual que se volvió positivo en 8.574 dólares.
El desempeño de la empresa fue impulsado por el crecimiento en los Productos Teranósticos, que vieron un aumento anual del 17% a 8 millones de dólares, y los ingresos récord en Productos de Cobalto, que subieron un 128% a 2,4 millones de dólares. Sin embargo, los productos de Medicina Nuclear experimentaron una disminución del 20% debido a la escasez de materias primas. El nuevo segmento de Dispositivos Médicos de la empresa se está preparando para la comercialización de productos en 2025.
El EBITDA no GAAP mejoró en un 332% a 615.934 dólares, mientras que el EBITDA ajustado alcanzó 1,2 millones de dólares, un aumento del 379% respecto a 2023.
International Isotopes (INIS)는 2024 회계연도 4분기 및 연간 재무 결과를 발표했습니다. 4분기 수익은 24% 증가하여 390만 달러에 달했으며, 연간 수익은 1390만 달러로 역사적인 최고치를 기록하며 전년 대비 13% 증가했습니다. 회사는 4분기 순이익이 325% 증가하여 245,819 달러에 이르고, 연간 순이익이 8,574 달러로 긍정적인 결과를 달성하며 수익성이 크게 개선되었습니다.
회사의 성장은 테라노스틱 제품의 17% 연간 증가로 800만 달러에 도달했으며, 코발트 제품의 기록적인 수익이 128% 증가하여 240만 달러에 달했습니다. 그러나 원자재 부족으로 인해 핵의학 제품은 20% 감소했습니다. 회사의 새로운 의료 기기 부문은 2025년 제품 상용화를 준비하고 있습니다.
비 GAAP EBITDA는 332% 증가하여 615,934 달러에 달했으며, 조정된 EBITDA는 120만 달러에 이르러 2023년 대비 379% 증가했습니다.
International Isotopes (INIS) a rapporté des résultats financiers solides pour le quatrième trimestre et l'exercice 2024. Les revenus du quatrième trimestre ont augmenté de 24 % pour atteindre 3,9 millions de dollars, tandis que les revenus annuels ont atteint un niveau record de 13,9 millions de dollars, en hausse de 13 % par rapport à l'année précédente. L'entreprise a réalisé des améliorations significatives de sa rentabilité, avec un bénéfice net du quatrième trimestre en hausse de 325 % à 245 819 dollars et un bénéfice net annuel devenu positif à 8 574 dollars.
La performance de l'entreprise a été soutenue par la croissance des Produits Théranostiques, qui ont enregistré une augmentation annuelle de 17 % pour atteindre 8 millions de dollars, et des revenus records dans les Produits de Cobalt, en hausse de 128 % à 2,4 millions de dollars. Cependant, les produits de Médecine Nucléaire ont connu une baisse de 20 % en raison de pénuries de matières premières. Le nouveau segment des Dispositifs Médicaux de l'entreprise se prépare à la commercialisation des produits en 2025.
Le EBITDA non-GAAP a augmenté de 332 % pour atteindre 615 934 dollars, tandis que l'EBITDA ajusté a atteint 1,2 million de dollars, soit une augmentation de 379 % par rapport à 2023.
International Isotopes (INIS) berichtete über starke finanzielle Ergebnisse für das vierte Quartal und das Geschäftsjahr 2024. Die Einnahmen im vierten Quartal stiegen um 24% auf 3,9 Millionen Dollar, während die Gesamteinnahmen des Jahres mit 13,9 Millionen Dollar einen historischen Höchststand erreichten, was einem Anstieg von 13% im Jahresvergleich entspricht. Das Unternehmen erzielte erhebliche Verbesserungen bei der Rentabilität, wobei der Nettogewinn im vierten Quartal um 325% auf 245.819 Dollar stieg und der Nettogewinn des gesamten Jahres positiv bei 8.574 Dollar lag.
Die Leistung des Unternehmens wurde durch das Wachstum der Theranostics-Produkte angetrieben, die einen jährlichen Anstieg von 17% auf 8 Millionen Dollar verzeichneten, sowie durch Rekordumsätze bei Kobalt-Produkten, die um 128% auf 2,4 Millionen Dollar stiegen. Die Produkte der Nuklearmedizin erlitten jedoch einen Rückgang von 20% aufgrund von Rohstoffengpässen. Das neue Segment der Medizinprodukte des Unternehmens bereitet sich auf die Produktkommerzialisierung im Jahr 2025 vor.
Das Non-GAAP EBITDA verbesserte sich um 332% auf 615.934 Dollar, während das bereinigte EBITDA 1,2 Millionen Dollar erreichte, was einem Anstieg von 379% gegenüber 2023 entspricht.
- Record annual revenue of $13.9M, up 13%
- Q4 revenue increased 24% to $3.9M
- Turned profitable with $8,574 net income vs $869K loss
- Adjusted EBITDA up 379% to $1.2M
- Theranostics segment revenue up 17% to $8M
- Cobalt Products revenue grew 128% to $2.4M
- Nuclear Medicine segment revenue down 20% due to material shortage
- Medical Devices segment had negligible sales
- Q4 Theranostics revenue decreased 3.4%
- Revenues for fourth quarter increased
24% to$3.9 million 13% to$13.9 million - Net Income in the fourth quarter increased
325% to$245,819 101% to$8,574 - Full year non-GAAP EBITDA(1) increased
332% , to$615,934 $1,236,282 379% from the prior year.
Increases in both periods were driven primarily by continued growth of Theranostics Products and a record revenue year for Cobalt Products, offset by a down year in Nuclear Medicine products due to a prolonged raw material outage in 2024 and continued investment in the Medical Device segment's start-up.
(1) See "Non-GAAP Financial Measures" below.
Shahe Bagerdjian, President & CEO of the Company, said, "2024 was another historic year for INIS having posted record revenue in consecutive years and an operationally profitable year. The combined efforts of R&D, strategic marketing, and operational improvements have helped unlock tremendous improvement in our EBITDA numbers. Despite a slow first half due to raw material shortages, we finished the year very strong. I anticipate that 2025 will continue to build on our momentum as we continue to launch new products and expand our market share across all our segments."
Segment Results
Theranostics Products
Revenue from the sale of Theranostics Products for the fourth quarter of 2024 was
Nuclear Medicine Standards Segment
Revenue from Nuclear Medicine products for the fourth quarter of 2024 was
Cobalt Products
Revenue from the sale of Cobalt Products for the fourth quarter of 2024 was
Medical Devices Products
Medical Devices is a new reportable business segment for fiscal year 2024. We had negligible sales in 2024. We have invested in this segment throughout 2023 and 2024, and anticipate additional investments in 2025 as we ramp to commercialization of products in 2025. This segment will include The Swirler® and Tru-Fit™ Mouthpiece, Xenon System, and related accessories under the RadVent brand as well as partnering with leading manufacturers for distribution through our network of global distributors. Additionally, the Company has investments in a joint venture arrangement for our EasyFill Automated Iodine Capsule System and recently signed an exclusive distribution and servicing agreement for the full line of Scintomics ATT products. Our Medical Device segment is focused on bringing products to market which help the industry improve safety, efficiency, and patient access to radiopharmaceutical diagnostics and therapeutics.
Three Months Ended December 31, | Twelve months ended - December 31, 2024 | ||||||||||
2024 | 2023 | % | 2024 | 2023 | % | ||||||
Sale of product | $ | 3,901,625 | $ | 3,147,129 | 24 % | $ | 13,899,760 | $ | 12,267,385 | 13 % | |
Gross profit | $ | 2,315,503 | $ | 1,963,659 | 18 % | $ | 8,648,553 | $ | 7,378,976 | 17 % | |
Total Operating Expense | $ | 2,041,887 | $ | 2,054,466 | -1 % | $ | 8,641,652 | $ | 8,155,275 | 6 % | |
Operating Profit (Loss) Before | $ | 273,616 | $ | (90,807) | 401 % | $ | 6,901 | $ | (776,299) | 101 % | |
Other Income (Expense) | $ | (27,797) | $ | (18,248) | -52 % | $ | 1,673 | $ | (92,717) | 102 % | |
Net Income (Loss) | $ | 245,819 | $ | (109,055) | 325 % | $ | 8,574 | $ | (869,016) | 101 % | |
Net income per common | $ | — | $ | — | $ | — | $ | — | |||
Net income per common | $ | — | $ | — | $ | — | $ | — | |||
Weighted avg. shares | 523,537,053 | 519,781,648 | 522,289,354 | 517,777,847 | |||||||
Weighted avg. shares | 523,537,053 | 519,781,648 | 522,289,354 | 517,777,847 | |||||||
Full Earnings Release Available on INIS Website
A full version of this earnings release is available on our Investor Center website at https://intisoid.com/investor-center/.
Non-GAAP Financial Measures
This press release contains financial measures that do not comply with
These non-GAAP financial measures are supplemental measures to our results of operations as reported under GAAP. Our management uses these measures to better analyze our financial results and business operations. In management's opinion, these non-GAAP measures are useful to investors and other users of our financial statements by providing greater transparency into the ongoing operating performance of the Company and its future outlook. Such measures should not be considered alternatives to net income or any other performance measures derived in accordance with GAAP. The Company's measurement of EBITDA and Adjusted EBITDA may not be comparable to similar measures of other companies as they are not performance measures calculated in accordance with GAAP.
Non-GAAP Reconciliations
Twelve Months Ended December 31, | |||||||
2024 | 2023 | $ Change | % Change | ||||
Net income (loss) | $ | 8,574 | $ | (869,016) | $ | 877,590 | 101 % |
Interest expense, net | 206,293 | 252,890 | (46,597) | 18 % | |||
Provision for income taxes | — | — | — | — | |||
Depreciation and amortization | 401,067 | 350,094 | 50,973 | 15 % | |||
EBITDA | 615,934 | (266,032) | 881,966 | 332 % | |||
Non-cash stock-based compensation | 199,420 | 464,041 | (264,621) | -57 % | |||
Gain on disposal of property, plant, and | (13,492) | — | |||||
NRC Enforcement Matters (a) | 233,852 | — | |||||
Medical Devices Buildout (b) | 200,568 | 59,923 | 140,645 | 235 % | |||
Adjusted EBITDA | $ | 1,236,282 | $ | 257,932 | $ | 978,350 | 379 % |
(a) Represents costs for an NRC violation that occurred in 2022, including legal, root cause audits, and NRC fines. |
(b) Represents legal work for initial buildout of the Medical Devices business segment |
International Isotopes Inc. Safe Harbor Statement
Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements with respect to the Company's future growth expectations. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance, or achievements of International Isotopes Inc. to be materially different from any future results, performance or achievements of the Company expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company's filings with the Securities and Exchange Commission at www.sec.gov, including its Annual Report on Form 10-K for the year ended December 31, 2024. Investors, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward- looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and International Isotopes, Inc. and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
About International Isotopes Inc.
International Isotopes Inc. (INIS), established in 1995, with its headquarters in
International Isotopes Contact: intisoid.com 208.524.5300 | Investor Relations Contact: David Drewitz, Creative Options Communications Investor and Public Relations david@creativeoptionscommunications.com www.creativeoptionsmarketing.com 972.814.5723 |
View original content:https://www.prnewswire.com/news-releases/international-isotopes-inc-announces-fiscal-results-for-the-fourth-quarter-and-fiscal-year-2024-302390956.html
SOURCE International Isotopes Inc.
FAQ
What were INIS's key financial achievements in fiscal year 2024?
How did INIS's Theranostics Products segment perform in 2024?
What caused the decline in INIS's Nuclear Medicine segment during 2024?
What are INIS's plans for its new Medical Devices segment in 2025?
